Salt 628

• US 8,232,296 B2
• Filed: 02/16/2010
• Issued: 07/31/2012
• Est. Priority Date: 02/20/2009
• Status: Active Grant

• Current Assignee: Astrazeneca AB (Astrazeneca PLC)
• Original Assignee: Astrazeneca AB (Astrazeneca PLC)
• Inventors: Briggner, Lars-Erik, Klingstedt, Per Tomas, Lönn, Hans Roland, Zuban, Robert, Alcaraz, Marie-Lyne, Nixon, Robert Anthony, Watts, Andrew James
• Primary Examiner(s): MORRIS, PATRICIA L
• Application Number:
  US12/706,313
• Publication Number:
  US 20100216843A1
• Time in Patent Office: 896 Days
• Field of Search: 546/256, 514/333
• US Class Current: 514/333
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 11/08 Bronchodilators
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07D 401/14 containing three or more hetero rings

Abstract

6-Methyl-5-(1-methyl-1H-pyrazol-5-yl)-N-{[5-(methylsulfonyl)pyridin-2-yl]methyl}-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide 4-methylbenzenesulfonate and a novel crystalline form thereof are disclosed together with processes for preparing such salt and form, pharmaceutical compositions comprising such a salt and form, and the methods of treatment using such a salt and form.

Claims

1. The compound 6-methyl-5-(1-methyl-1H-pyrazol-5-yl)-N-{[5-methylsulfonyl)pyridin-2-yl]-methyl}-2-oxo-1-[3-trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide 4-methylbenzenesulfonate Form A, wherein said Form A has an X-ray powder diffraction pattern measured using CuK_α

radiation with at least one specific peak at 2θ

=about 5.1, 7.3, 8.9, 17.0 or 17.8°

.

2. The compound according to claim 1 wherein said Form A has an X-ray powder diffraction pattern measured using CuK_α

radiation with specific peaks at 2θ

=about 5.1, 7.3, 8.9, 17.0 and 17.8°

.

3. The compound according to claim 1 wherein said Form A has an X-ray powder diffraction pattern measured using CuK_α

radiation substantially the same as that shown in FIG. 1.